#Neutralization and #Stability of #JN1-derived #LB1, #KP23, #KP3 and #KP311 #Subvariants http://biorxiv.org/cgi/content/short/2024.09.04.611219v1?rss=1

We report on the neutralizing #antibody (nAb) #escape, infectivity, #fusion, and stability of these subvariants-LB.1, KP.2.3, KP.3, and KP.3.1.1. Our findings demonstrate that all of these subvariants are highly evasive of nAbs elicited by bivalent #mRNA #vaccine, the #XBB15 monovalent mumps virus-based vaccine, or from infections during the BA.2.86/JN.1 wave.

#Pemivibart is less active against recent #SARS-CoV-2 #JN1 #sublineages http://biorxiv.org/cgi/content/short/2024.08.12.607496v1?rss=1

Pemivibart neutralized both JN.1 and #KP2 in vitro with comparable activity, whereas its potency was decreased slightly against #LB1, #KP23, and #KP3 but substantially against #KP311. Critically, the 50% inhibitory concentration of pemivibart against KP.3.1.1 was ~6 g/mL, or ~32.7 fold higher than that of JN.1.

The virological characteristics
of SARS-CoV-2 KP.3.1.1

@systemsvirology

These results suggest that KP.3.1.1 has the potential to be predominant due to its higher infectivity and increased immune evasion. In particular, #S31del in spike, the common mutation in KP.3.1.1, LB.1 and KP.2.3, is likely to be a key mutation.

KP.3.1.1 (JN.1.11.1.3.1.1). This variant harbors these mutations.
KP.3.1.1 spike = KP.3 spike + S31del. 4/

#KP3111 #LB1 #KP23

https://threadreaderapp.com/thread/1813465697252688273.html

Nuevas #variantes de #covid19 circulan en #Guatemala https://boletinaldia.sld.cu/aldia/2024/07/27/nuevas-variantes-de-covid-19-circulan-en-guatemala/

La cartera sanitaria refirió un reciente informe de la dirección del Laboratorio Nacional que confirmó por primera vez las cepas #KP y sus sublinajes #KP11, #KP113, #KP2, #KP22, #KP23, #KP323.

#Virological characteristics of the #SARS-CoV-2 #KP3, #LB1, and #KP23 #variants, Lancet Infect Dis.: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(24)00415-8/fulltext?rss=yes

JN.1 subvariants such as LB.1 (JN.1.9.2.1) and KP.2.3 (JN.1.11.1.2·3), which convergently acquired a deletion at the 31st position in S (Ser31del) in addition to the aforementioned substitutions, have emerged and spread as of June, 2024 (appendix pp 12–13).

#Virological characteristics of the #SarsCoV2 #KP3, #LB1 and #KP23 #variants, BioRxIV, https://www.biorxiv.org/content/10.1101/2024.06.05.597664v1?rss=1

Our results suggest that S #substitutions convergently acquired in #JN1 #subvariants contribute to immune evasion, & increase their Re when compared to parental JN.1. LB.1 & KP.2.3 exhibited higher pseudovirus #infectivity & more immune resistance than KP.2. Data suggest that S:S31del is critical to exhibit +infectivity, +immune evasion, & potentially contributes to increased Re.